Loading...
XLON
OBI
Market cap65mUSD
Dec 05, Last price  
11.39GBP
1D
1.24%
1Q
-25.31%
IPO
-80.36%
Name

Ondine Biomedical Inc

Chart & Performance

D1W1MN
XLON:OBI chart
P/E
P/S
43.85
EPS
Div Yield, %
Shrs. gr., 5y
7.13%
Rev. gr., 5y
34.59%
Revenues
2m
+70.32%
00001,619,2091,605,485912,3261,030,2311,532,838412,000373,000464,0001,791,0002,569,000638,0001,203,0002,049,000
Net income
-19m
L+32.51%
-73,290-1,537,483-84,343-8,539,069-11,963,096-13,154,325-10,269,721-4,595,474-3,256,795-6,434,000-16,656,000-14,164,000-16,917,000-82,816,000-20,784,000-14,412,000-19,098,000
CFO
-14m
L-16.47%
-49,50125,261-66,204-8,386,839-10,844,066-11,904,485-8,928,676-3,438,721-2,720,118-5,268,000-10,084,000-7,551,000-6,331,000-12,540,000-16,345,000-13,653,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The company's lead product is Steriwave, a photodisinfection based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections. Its product pipeline also includes development of a topical antiviral therapy for the upper respiratory tract that reduces SARS-CoV-2 titre and transmission; a solution for treatment of chronic rhinosinusitis; OND1002, a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and OND1003, a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.
IPO date
Dec 06, 2021
Employees
18
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT